Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Muriel Wartelle"'
Autor:
Sandrine Mercier, François Lion, Benjamin Besse, Loic Verlingue, Bruno Thuillier, Muriel Wartelle, Antoine Hollebecque, Christophe Massard, Mikael Azoulay, Julie Delorme, Valentin Charvet, Jean-Charles Soria
Publikováno v:
JCO Clinical Cancer Informatics. :709-718
PURPOSE Early discontinuation affects more than one third of patients enrolled in early-phase oncology clinical trials. Early discontinuation is deleterious both for the patient and for the study, by inflating its duration and associated costs. We ai
Autor:
François Lion, Bruno Thuillier, Julie Delorme, Jean-Charles Soria, Benjamin Besse, Muriel Wartelle, Sandrine Mercier, Loic Verlingue, Mikael Azoulay, Antoine Hollebecque, Christophe Massard, Valentin Charvet
PurposeEarly discontinuation affects over one-third of patients enrolled in early-phase oncology clinical trials. Early discontinuation is deleterious both for the patient and for the study, by inflating its duration and associated costs. We aimed at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2283f3a07cbb2b0b2f6d41e7d9aa3ea3
https://doi.org/10.1101/2021.02.07.21249271
https://doi.org/10.1101/2021.02.07.21249271
Autor:
Elisabeth Chachaty, Federico Rotolo, Muriel Wartelle, François Blot, Jean-Pierre Pignon, Y. Hicheri, M. Mons, Bertrand Gachot, Annabelle Stoclin
Publikováno v:
Supportive Care in Cancer
Purpose Some publications suggest high rates of healthcare-associated infections (HAIs) and of nosocomial pneumonia portending a poor prognosis in ICU cancer patients. A better understanding of the epidemiology of HAIs in these patients is needed. Me
Autor:
Tiphaine Lambert, Stéphane Champiat, Léo Colmet-Daage, Brice Rauby, Eric Angevin, Marie Kerisit, Jean-Charles Soria, Antoine Hollebecque, Benjamin Besse, Muriel Wartelle, Nicolas Sanchez-Escobar Aladro, Jean-Yves Scoazec, Christophe Massard, François Lion, Loic Verlingue
Publikováno v:
Journal of Clinical Oncology. 37:2618-2618
2618 Background: Using multiple immune-checkpoint proteins (ICP) screening in clinical routine could improve the evaluation of patients’ prognosis and ultimately tailor their treatment choice. We have evaluated this hypothesis in the context of ear
Autor:
Rodrigo Arriagada, J.P. Pignon, Jeannette Soria, T. Le Chevalier, C. Le Pechoux, M. Tarayre, Muriel Wartelle, Myriam Lassalle, Jérôme Fayette, Pierre Ruffié
Publikováno v:
Journal of Clinical Oncology. 22:7215-7215
7215 Background: Patients with limited SCLC have a 5-year overall survival of 25% despite aggressive initial treatment. In order to reserve toxic therapeutics to patients who may benefit from it we searched for prognostic factors in large series of l